Adam Grossman, President and Chief Executive Officer of ADMA said, “We anticipate 2024 will be defined by continued top tier revenue and earnings growth, commitment to capital allocation strategies that we believe will maximize stockholder value, and further de-risking growth initiatives that have the potential to provide transformative upside to ADMA’s currently provided peak revenue and earnings potential. The combination of our continued success with ASCENIV and BIVIGAM, in addition to the potential contribution from new growth opportunities, we believe positions us to continue to make a difference in patients’ lives and generate durable top and bottom-line growth for years to come.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ADMA:
- ADMA Biologics Announces $135 Million Non-Dilutive Refinancing of Credit Facilities with Ares Management
- ADMA Biologics Announces FDA Approval for BIVIGAM® in the Pediatric Patient Setting for Those 2 Years of Age and Older
- ADMA Biologics announces FDA approval of BIVIGAM in pediatric patient setting
- ADMA Biologics receives FDA approval for tenth plasma collection cent er
- ADMA BioCenters Receives FDA Approval for its Tenth Plasma Collection Center, Located in Laurel, MD
